ES2155134T3 - Derivados de imidazolidina y su utilizacion. - Google Patents

Derivados de imidazolidina y su utilizacion.

Info

Publication number
ES2155134T3
ES2155134T3 ES95926500T ES95926500T ES2155134T3 ES 2155134 T3 ES2155134 T3 ES 2155134T3 ES 95926500 T ES95926500 T ES 95926500T ES 95926500 T ES95926500 T ES 95926500T ES 2155134 T3 ES2155134 T3 ES 2155134T3
Authority
ES
Spain
Prior art keywords
rent
alquilpiperazinil
sterified
ceno
oalquenilo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95926500T
Other languages
English (en)
Inventor
Harukazu Fukami
Motoo Sumida
Shinjiro Niwata
Saki Kakutani
Masayuki Saitoh
Hiroshi Shibata
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Suntory Ltd
Original Assignee
Suntory Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suntory Ltd filed Critical Suntory Ltd
Application granted granted Critical
Publication of ES2155134T3 publication Critical patent/ES2155134T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C07D233/80—Two oxygen atoms, e.g. hydantoin with hetero atoms or acyl radicals directly attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/86—Oxygen and sulfur atoms, e.g. thiohydantoin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)

Abstract

DERIVADO DE IMIDAZOLIDINA REPRESENTADO POR LA FORMULA GENERAL (I) Y MEDICINAS QUE LO CONTIENEN COMO EL INGREDIENTE ACTIVO, EJEMPLOS REPRESENTATIVOS QUE INCLUYEN UN INHIBIDOR DE QUIMASA Y UN PREVENTIVO O REMEDIO PARA ENFERMEDADES CIRCULATORIAS O CARDIACAS CAUSADAS POR PALPITACIONES ANORMALES INDUCIDAS POR LA ANGIOTENSINA II, DONDE A Y B REPRESENTAN CADA UNO UN GRUPO DE HIDROCARBURO AROMATICO QUE PUEDE SER SUSTITUIDO POR UNO O MAS SUSTITUYENTES SELECCIONADOS DE ENTRE HALOGENO, C ALQUILO, ALCOXI, ALQUILENODIOXI, FENOXI, NITRO,CIANO, FENILO, ALCANOILAMINO, CARBOXILO QUE PUEDE SER ESTERIFICADO CON ALQUILO O ALQUENILO, CARBOXIALQUILO QUE PUEDE SER ESTERIFICADO CON ALQUILO O ALQUENILO, CARBOXIALQUILOXI QUE SER ESTERIFICADO CON ALQUILO OALQUENILO, N-ALQUILPIPERAZINIL CARBONILO, N-ALQUILPIPERAZINIL-CARBONIALQUILO, N-ALQUILOPIPERAZINIL-CARBONILALQUILOXI Y MORFOLINOCARBONILO; X REPRESENTA OXIGENO O SULFURO.
ES95926500T 1994-07-29 1995-07-26 Derivados de imidazolidina y su utilizacion. Expired - Lifetime ES2155134T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP20786794 1994-07-29
JP33370694 1994-12-07

Publications (1)

Publication Number Publication Date
ES2155134T3 true ES2155134T3 (es) 2001-05-01

Family

ID=26516513

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95926500T Expired - Lifetime ES2155134T3 (es) 1994-07-29 1995-07-26 Derivados de imidazolidina y su utilizacion.

Country Status (7)

Country Link
US (1) US5691335A (es)
EP (1) EP0721944B1 (es)
AT (1) ATE198743T1 (es)
AU (1) AU3086095A (es)
DE (1) DE69519921T2 (es)
ES (1) ES2155134T3 (es)
WO (1) WO1996004248A1 (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5912261A (en) * 1994-12-20 1999-06-15 Nippon Zoki Pharmaceutical Co., Ltd. Carboxyalkyl heterocyclic derivatives
US6197806B1 (en) 1995-12-20 2001-03-06 Nippon Zoki Pharmaceutical Co., Ltd. Eliminating agent for activated oxygen and free radicals
JPH10182460A (ja) * 1996-12-27 1998-07-07 Nippon Zoki Pharmaceut Co Ltd ３−デオキシグルコソン生成阻害剤
US20050267148A1 (en) * 1998-07-15 2005-12-01 Teijin Limited Benzimidazole derivative
CN1187337C (zh) 1998-07-15 2005-02-02 帝人株式会社 硫代苯并咪唑衍生物
KR100381214B1 (ko) * 1998-08-10 2003-09-22 주식회사 엘지생명과학 항암제로유용한이미다졸리딘-2,4-디온유도체및그의제조방법
EP1112749A4 (en) * 1998-08-20 2004-06-16 Senju Pharma Co PROPHYLAXIS OR REMEDIES FOR CIRCULATORY EYE DISTURBANCE
ATE326451T1 (de) * 1998-08-21 2006-06-15 Daiichi Asubio Pharma Co Ltd Chinazolin derivate und therapeutische verwendungen davon
AU754989B2 (en) 1998-11-16 2002-11-28 Nippon Zoki Pharmaceutical Co., Ltd. A therapeutic agent for intractable vasculitis
EP1136488A4 (en) * 1998-12-01 2002-06-12 Meiji Seika Kaisha SF2809-I, II, III. VI, V AND VI COMPOUNDS WITH CHYMASE INHIBITING EFFECT
WO2001030388A1 (en) * 1999-10-25 2001-05-03 Senju Pharmaceutical Co., Ltd. Tension-relieving agents for ciliary muscle
EP1142586B1 (en) 1999-11-01 2007-04-25 Daiichi Asubio Pharma Co., Ltd. Use of chymase inhibitors against vascular lipid deposition
US6300503B1 (en) * 1999-12-17 2001-10-09 Dixie Chemical Company Hydantoin intermediates for the synthesis of omapatrilat and methods for producing and using the same
KR20010108519A (ko) 2000-02-22 2001-12-07 도리이 신이치로 키마제 억제제를 유효성분으로 하는 선유증의 예방 또는치료약
DE60121695T2 (de) * 2000-02-22 2007-08-30 Daiichi Asubio Pharma Co., Ltd. Arzneimittel mit chymaseinhibitoren als wirksames mittel zur behandlung von dermatitis mit zweiphasigen hautreaktionen
AU3413501A (en) 2000-02-22 2001-09-03 Daiichi Asubio Pharma Co., Ltd. Preventive or therapeutic drugs for various eosinophilia-related diseases containing chymase inhibitors as the active ingredient
JP4711523B2 (ja) 2001-02-13 2011-06-29 日本臓器製薬株式会社 低アルブミン血症改善剤
JPWO2002083649A1 (ja) * 2001-04-11 2004-08-05 千寿製薬株式会社 新規イミダゾリジンジオン誘導体およびその医薬用途
MXPA05000536A (es) * 2002-07-30 2005-04-19 Sod Conseils Rech Applic Uso de los inhibidores de la quimasa para la prevencion y/o tratamiento de la falla de injertos arterio-venosos.
FR2845383B1 (fr) * 2002-10-04 2004-12-31 Fournier Lab Sa Composes derives de la 2-thiohydantoine et leur utilisation en therapeutique
WO2004031160A2 (fr) * 2002-10-04 2004-04-15 Laboratoires Fournier S.A. Composes derives de la 2-thiohydantoïne et leur utilisation pour le traitement du diabete
FR2845384B1 (fr) * 2002-10-04 2004-12-31 Fournier Lab Sa Composes derives de la 2-thiohydantoine et leur utilisation en therapeutique
ES2636943T3 (es) 2003-05-09 2017-10-10 Toray Industries, Inc. Beraprost y un inhibidor del sistema renina-angiotensina para usar en el tratamiento de enfermedades renales
US7423155B2 (en) 2003-11-14 2008-09-09 3M Innovative Properties Company N-sulfonyldicarboximide containing tethering compounds
US7361767B2 (en) * 2003-11-14 2008-04-22 3M Innovative Properties Company N-sulfonyldicarboximide containing tethering compounds
EP2299266A1 (en) 2003-12-19 2011-03-23 The Regents of the University of California Methods and materials for assessing prostate cancer therapies
NZ550102A (en) 2004-02-24 2010-10-29 Univ California Methods and materials for assessing prostate cancer therapies and compounds (thiohydantoine derivatives)
US7709517B2 (en) 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
US7544756B2 (en) 2005-09-30 2009-06-09 3M Innovative Properties Company Crosslinked polymers with amine binding groups
BRPI0709771B1 (pt) 2006-03-27 2022-01-25 The Regents Of The University Of California Composto e composição farmacêutica
NZ596260A (en) 2006-03-29 2013-05-31 Univ California Diarylthiohydantoin compounds
TWI469971B (zh) 2007-10-26 2015-01-21 Univ California 二芳基乙內醯脲類化合物
WO2010088195A1 (en) 2009-01-30 2010-08-05 Boehringer Ingelheim International Gmbh Azaquinazolinediones useful as chymase inhibitors
EP3124481B1 (en) 2010-02-16 2018-03-28 Aragon Pharmaceuticals, Inc. Androgen receptor modulators and uses thereof
WO2014052237A1 (en) 2012-09-26 2014-04-03 Aragon Pharmaceuticals, Inc. Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
EP2945628B1 (en) 2013-01-15 2020-04-15 Aragon Pharmaceuticals, Inc. Androgen receptor modulator in combination with abiraterone acetate and prednisone for treating prostate cancer
CA2929763A1 (en) * 2013-11-08 2015-05-14 Bayer Pharma Aktiengesellschaft Substituted uracils as chymase inhibitors
TWI726969B (zh) 2016-01-11 2021-05-11 比利時商健生藥品公司 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物
KR102521955B1 (ko) * 2016-06-14 2023-04-13 브리스톨-마이어스 스큅 컴퍼니 Apj 수용체 효능제로서의 4-히드록시-3-술포닐피리딘-2(1h)-온
WO2017218633A1 (en) * 2016-06-14 2017-12-21 Bristol-Myers Squibb Company 6-hydroxy-5-(phenyl/heteroarylsulfonyl)pyrimidin-4(1h)-one as apj agonists
WO2019023448A1 (en) * 2017-07-26 2019-01-31 Emory University INHIBITORS OF NADPH OXIDASE AND THEIR USE
KR20240096623A (ko) 2017-10-16 2024-06-26 아라곤 파마슈티컬스, 인코포레이티드 비-전이성 거세-저항성 전립선암의 치료를 위한 항-안드로겐

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1207391B (de) * 1962-05-30 1965-12-23 Degussa Verfahren zur Herstellung von 3-Benzoyl-5, 5-dimethylhydantoinen
US4166124A (en) * 1970-05-15 1979-08-28 U.S. Philips Corporation Insecticidal 2,6-dihalobenzoyl urea derivatives
JPS5371073A (en) * 1976-12-03 1978-06-24 Sumitomo Chem Co Ltd 1-cyclic alkyl carbonyl-3(3,5-dihalogenophenyl)hydantoin derivs., process fo r their preparation and fungicides for agriculture and horti culture contg. the same as active constituents
JPS5855468A (ja) * 1981-09-25 1983-04-01 Sumitomo Chem Co Ltd ５−クロロヒダントイン誘導体、その製造法およびそれを有効成分として含有する殺虫剤
US4474796A (en) * 1983-02-04 1984-10-02 Sumitomo Chemical Company, Limited Insecticidal substituted hydantoins
JPH068281B2 (ja) * 1985-09-19 1994-02-02 持田製薬株式会社 ヒダントイン誘導体及びそれを有効成分とするアルド−スレダクタ−ゼ阻害剤

Also Published As

Publication number Publication date
DE69519921T2 (de) 2001-06-13
DE69519921D1 (de) 2001-02-22
US5691335A (en) 1997-11-25
EP0721944B1 (en) 2001-01-17
ATE198743T1 (de) 2001-02-15
EP0721944A4 (en) 1997-01-02
AU3086095A (en) 1996-03-04
EP0721944A1 (en) 1996-07-17
WO1996004248A1 (en) 1996-02-15

Similar Documents

Publication Publication Date Title
SE8102193L (sv) Terapeutiskt aktiv organisk forening och dess anvendning
AR001332A1 (es) Nuevos compuestos antagonistas de la taquicinina, proceso para obtenerlos y composiciones farmaceuticas que los contienen.
PE20020722A1 (es) Derivados de glucopiranosiloxipirazol como inhibidor del sglt2 humano
ES2172585T3 (es) Derivado de benzoimidazol.
ES2058291T3 (es) Derivados de piperazinilo de las purinas e isosteros de las mismas como agentes hipoglucemicos.
ES2138971T3 (es) Regulador de la apoptosis.
MX9202747A (es) Nuevas sulfonamidas y procedimientos para su preparacion.
ES2190430T3 (es) Nuevas sulfonamidas.
GT199900067A (es) Nuevas 4-fenilpiperidinas para el tratamiento dedermatosis prurìtica.
SV1995000007A (es) Derivados del acido micofenolico 5-substituidos.
ES2061471T3 (es) Derivados de la piridina, compuestos farmaceuticos que comprenden la misma, su utilizacion para la fabricacion de medicamentos con valor terapeutico o preventivo y procedimiento para su fabricacion.
ES2161697T3 (es) Peptidos agonistas de amilina y usos de los mismos.
AR221094A1 (es) Derivados de n-((pirimidin o triazin)-aminocarbonil)-2-carbonil-benceno-sulfonamida,procedimiento para obtenerlos,compuesto empleado como intermedio,procedimiento para obtenerlo y composicion para el control de la vegetacion indeseable que contiene los nuevos derivados
ATE165827T1 (de) Herstellung von n-acetylneuraminsäure-derivaten
ES2038074A1 (es) Nuevos derivados de benzimidazol, su preparacion y su aplicacion como medicamentos.
ATE39357T1 (de) Derivate von griseolicsaeure und ihre verwendung.
ECSP930949A (es) Derivados de 2- imidazolina -5- onas y 2- imidazolina- 5 tionas fungicidas
ES2117664T3 (es) Carboximetilmanoglucanos y derivados de los mismos.
ES2103825T3 (es) Composiciones farmaceuticas que contienen 5-difluorometoxi-2-(3,4-dimetoxi-2-piridil)-metilsulfinil)bencimidazol y un agente anti-helicobacter para el tratamiento de trastornos gastrointestinales.
ES2099865T3 (es) Ciclopentanoperhidrofenantreno-17beta-(3-furil)-3-derivados y composiciones farmaceuticas que comprenden los mismos para el tratamiento de trastornos cardiovasculares.
ES2036560T3 (es) Un metodo para preparar una composicion sinergicamente activa para el tratamiento de hipertension.
ES2081834T3 (es) Pirrolidin-2-onas 4-metil y 4-etil sustituidas.
ES2036238T3 (es) Derivados de hidroxietil-azolilo.
ES2058461T3 (es) Derivados de la 3(2h)-piridazinona, procedimientos para su obtencion y su empleo para la lucha contra las pestes.
ES2039719T3 (es) Procedimiento para preparar un agente terapeutico para el tratamiento de la enfermedad de ulcera peptica.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 721944

Country of ref document: ES